Ahithophel Weissberger

Mannkind: Overlooked Biotech With Excellent Prospects (Part IV)

V.P.:
"However, management has already burned $1.1 billion in develpoing TI. ... Tell me, how soon do you think the management can earn the $1.1 billion burnt in TI's development so far?" -- V.P.

That is an interesting question, but it is only relevant to whether it was worth it for Mannkind to have invested the $1.1 billion that it did back then. That is not the question on the table now and it is not really a relevant question for an investor who is considering buying MNKD now. Mannkind's market cap is right now $290 million. If you buy a share in Mannkind NOW, you are buying this company (with a drug that I believe will definitely pass FDA inspection and probably do well in the marketplace) for a fraction of its worth. Ask yourself: If Technosphere Insulin IS successful, will Mannkind deserve to be worth only $290 million? That is the only relevant question when it comes to valuating MNKD the stock (in addition, of course, to whether you think Technosphere Insulin will be succesfull or not). We don't care whether the original investors make back their money with enough profit to make it worth it.